Abstract:The gut-liver axis covers the bidirectional communication between the gut and the liver, and thus includes signals from liver-to-gut (e.g., bile acids, immunoglobulins) and from gut-to-liver (e.g., nutrients, microbiota-derived products, and recirculating bile acids). In a healthy individual, liver homeostasis is tightly controlled by the mostly tolerogenic liver resident macrophages, the Kupffer cells, capturing the gut-derived antigens from the blood circulation. However, disturbances of the gut-liver axis have been associated to the progression of varying chronic liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and primary sclerosing cholangitis. Notably, changes of the gut microbiome, or intestinal dysbiosis, combined with increased intestinal permeability, leads to the translocation of gut-derived bacteria or their metabolites into the portal vein. In the context of concomitant or subsequent liver inflammation, the liver is then infiltrated by responsive immune cells (e.g., monocytes, neutrophils, lymphoid, or dendritic cells), and microbiota-derived products may provoke or exacerbate innate immune responses, hence perpetuating liver inflammation and fibrosis, and potentiating the risks of developing cirrhosis. Similarly, food derived antigens, bile acids, danger-, and pathogen-associated molecular patterns are able to reshape the liver immune microenvironment. Immune cell intracellular signaling components, such as inflammasome activation, toll-like receptor or nucleotide-binding oligomerization domain-like receptors signaling, are potent targets of interest for the modulation of the immune response. This review describes the current understanding of the cellular landscape and molecular pathways involved in the gut-liver axis and implicated in chronic liver disease progression. We also provide an overview of innovative therapeutic approaches and current clinical trials aiming at targeting the gut-liver axis for the treatment of patients with chronic liver and/or intestinal diseases.

The contribution of sterile inflammation to the fatty liver disease and the potential therapies

STING-mediated inflammation contributes to Gao binge ethanol feeding model

Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease

Inflammasome: A Double-Edged Sword in Liver Diseases

Role of inflammatory response in liver diseases: Therapeutic strategies

Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases

Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation

Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools

The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway

Molecular mechanisms in the pathogenesis of metabolically associated fatty liver disease

Treating inflammation to combat non-alcoholic fatty liver disease

NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors

Cellular Interplay as a Consequence of Inflammatory Signals Leading to Liver Fibrosis Development

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

Inflammatory liver diseases and susceptibility to sepsis

Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Innate immunity and nonalcoholic fatty liver disease

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease

Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease

The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)

The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis